**Perspective**
Volume 08:05, 2024

Journal of Microbial Pathogenesis

ISSN: 2684-4931 Open Access

# Agents that Attack the Bacterial Cell Wall as Weapons against Gram-positive Infections

**Mira Tamsin***

*Department of Bacteriology, Shiraz University, Shiraz, Fars Province, Iran*

## Introduction

The bacterial cell wall is an essential structural component that ensures the survival of bacteria under various environmental conditions. For Gram-positive bacteria, the cell wall not only provides structural integrity but also plays a pivotal role in interactions with the host and the bacterial pathogen's virulence. Gram-positive bacteria, characterized by a thick peptidoglycan layer, are involved in various infections, from minor skin infections to life-threatening diseases such as pneumonia, sepsis, and meningitis. Due to the clinical significance of these infections and the growing problem of antibiotic resistance, agents that target the bacterial cell wall have become a crucial part of the antimicrobial arsenal. This article examines the role of cell wall-targeting agents in combating Gram-positive infections, exploring the underlying mechanisms, effectiveness, and future perspectives of these agents in treating resistant bacterial strains [1].

Gram-positive bacteria differ from Gram-negative bacteria mainly in their cell wall composition. Gram-positive bacteria have a thick peptidoglycan layer, which accounts for their ability to retain crystal violet dye in the Gram-staining process, distinguishing them under the microscope. This thick cell wall, comprising numerous layers of peptidoglycan, serves as a significant barrier to external agents and is integral to bacterial cell survival, making it a highly effective target for antibiotics. Peptidoglycan synthesis and maintenance are complex processes involving several enzymes and pathways, such as the penicillin-binding proteins (PBPs) that catalyze the final stages of peptidoglycan cross-linking. By disrupting these enzymes and pathways, antibiotics can weaken the bacterial cell wall, leading to cell lysis and death [2].

## Description

One of the most well-known classes of antibiotics targeting the bacterial cell wall is the β-lactams, which include penicillins, cephalosporins, carbapenems, and monobactams. These antibiotics function by inhibiting PBPs, enzymes responsible for the cross-linking of peptidoglycan strands. Without cross-linking, the structural integrity of the cell wall is compromised, leading to bacterial cell death due to osmotic instability. Penicillins were among the first antibiotics discovered and remain an essential tool in treating Gram-positive infections. However, the emergence of resistance mechanisms, such as β-lactamase production and alterations in PBPs, has limited the efficacy of β-lactams. To combat these resistance mechanisms, researchers have developed β-lactamase inhibitors that can be combined with β-lactam antibiotics, thereby restoring their effectiveness against resistant strains [3].

Another critical class of antibiotics targeting the bacterial cell wall is the glycopeptides, with vancomycin being the most prominent example. Vancomycin and related glycopeptide antibiotics interfere with peptidoglycan synthesis by binding to the D-Ala-D-Ala terminus of the peptidoglycan precursor, preventing its incorporation into the cell wall. This action effectively halts cell wall synthesis, leading to bacterial cell death. Vancomycin has been a cornerstone in treating infections caused by MRSA and other resistant Gram-positive bacteria for decades. However, the emergence of vancomycin-resistant strains, particularly VRE, has posed a significant clinical challenge. Resistance to vancomycin occurs through the alteration of the D-Ala-D-Ala target site, which reduces vancomycin's binding affinity, rendering it less effective. As a response, newer lipoglycopeptides, such as telavancin and dalbavancin, have been developed [4].

Daptomycin is a unique antibiotic that also targets the bacterial cell wall but through a different mechanism compared to β-lactams and glycopeptides. It is a lipopeptide that binds to the bacterial cell membrane in a calcium-dependent manner, leading to membrane depolarization, disruption of cell wall synthesis, and eventual cell death. Daptomycin has proven particularly effective against Gram-positive pathogens, including MRSA and VRE. Its unique mechanism of action makes it an essential agent for treating infections caused by multi-drug resistant Gram-positive bacteria. However, daptomycin is not effective for treating pulmonary infections, as it is inactivated by pulmonary surfactant. Despite this limitation, daptomycin remains a vital antibiotic for treating serious Gram-positive infections, especially when other antibiotics are ineffective [5].

## Conclusion

Bacteriophages can produce enzymes, such as lysins, that degrade the bacterial cell wall, leading to bacterial lysis. This approach has shown promise in experimental studies and may offer a viable treatment option for infections caused by antibiotic-resistant Gram-positive bacteria. Moreover, antimicrobial peptides, which are part of the innate immune system in many organisms, are being investigated for their ability to disrupt bacterial cell membranes and cell walls. These peptides have a broad spectrum of activity and may serve as adjunctive therapies to traditional antibiotics.

In conclusion, agents that target the bacterial cell wall are indispensable weapons against Gram-positive infections. The effectiveness of antibiotics such as β-lactams, glycopeptides, daptomycin, and fosfomycin has proven critical in treating a wide range of infections caused by Gram-positive bacteria, including those resistant to multiple drugs. However, the emergence of resistance mechanisms among Gram-positive pathogens has underscored the need for novel antibiotics and alternative therapeutic strategies. Advances in understanding bacterial cell wall synthesis and resistance mechanisms have paved the way for the development of new antibiotics and adjunctive therapies, offering hope in the battle against resistant Gram-positive infections. As research into both traditional and novel agents continues, the future of combating Gram-positive infections may see a combination of antibiotic and non-antibiotic approaches, providing a robust and multifaceted strategy to address the global challenge of antibiotic resistance.

## Acknowledgement

None.

***Address for Correspondence:** Mira Tamsin, Department of Bacteriology, Shiraz University, Shiraz, Fars Province, Iran, E-mail: miratamsin@yahoo.com*



**Received:** 11 September, 2024, Manuscript No. jmp-24-152183; **Editor Assigned:** 13 September, 2024, Pre QC No. P-152183; **Reviewed:** 24 September, 2024, QC No. Q-152183; **Revised:** 30 September, 2024, Manuscript No. R-152183; **Published:** 07 October, 2024, DOI: 10.37421/2684-4931.2024.8.208

## Conflict of Interest

None.

## References


1. Queenan, Anne Marie and Karen Bush. "Carbapenemases: The versatile β-lactamases." *Clin Microbiol Rev* 20 (2007): 440-458.
2. Philippon, Alain, Guillaume Arlet, Roger Labia and Bogdan I. Iorga. "Class C β-lactamases: Molecular characteristics." *Clin Microbiol Rev* 35 (2022): e00150-21.
3. Fishovitz, Jennifer, Juan A. Hermoso, Mayland Chang and Shahriar Mobashery. "Penicillin-binding protein 2a of methicillin-resistant *Staphylococcus aureus*." *IUBMB life* 66 (2014): 572-577.
4. Schmelcher, Mathias, David M. Donovan and Martin J. Loessner. "Bacteriophage endolysins as novel antimicrobials." *Fut Microbiol* 7 (2012): 1147-1171.
5. Loessner, Martin J. "Bacteriophage endolysins—Current state of research and applications." *Curr Opin Microbiol* 8 (2005): 480-487.


**How to cite this article:** Tamsin, Mira. “Agents that Attack the Bacterial Cell Wall as Weapons against Gram-positive Infections.” *J Microb Path* 8 (2024): 208.